Abstract: A light-guide optical element and a method for manufacturing the same, includes: a coating step including forming at least one functional coating on a surface of a substrate, and cutting the substrate to form at least one optical coating strip; a mounting step including placing at least one optical coating strip in a storage space of a first substrate; an assembling step including combining a second substrate corresponding to the first substrate with the first substrate, so that the at least one optical coating strip is positioned between the first substrate and the second substrate, forming a semi-finished product; and a cutting step including cutting the semi-finished product into at least one finished light-guide optical element, and the at least one finished light-guide optical element includes the at least one optical coating strip.

Abstract: A method is provided including forming a first layer over a substrate and forming an adhesion layer over the first layer. The adhesion layer has a composition including an epoxy group. A photoresist layer is formed directly on the adhesion layer. A portion of the photoresist layer is exposed to a radiation source. The composition of the adhesion layer and the exposed portion of the photoresist layer cross-link using the epoxy group. Thee photoresist layer is then developed (e.g., by a negative tone developer) to form a photoresist pattern feature, which may overlie the formed cross-linked region.

Abstract: The present disclosure is related to a conjugate of an active drug and a glycosaminoglycan, such as hyaluronic acid (HA). For example, the active drug can be lenalidomide, nimesulide, or gemcitabine. The conjugate of the present disclosure is useful in the treatment of certain cancers.

Abstract: Disclosed herein are hyaluronic acid (HA)-nimesulide conjugates having one or two disaccharide units.

Abstract: The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: The present disclosure relates to chimeric heavy chain constant domains having reduced effector function. Also disclosed are recombinant polypeptides comprising such chimeric heavy chain constant domains, including antibodies such as multispecific antibodies, fusion proteins, and other recombinant proteins. Nucleic acids encoding such recombinant polypeptides are also disclosed, as well as cells expressing such recombinant polypeptides and pharmaceutical compositions comprising such recombinant polypeptides.

Abstract: Semiconductor processing apparatuses and methods are provided in which an electrostatic discharge (ESD) prevention layer is utilized to prevent or reduce ESD events from occurring between a semiconductor wafer and one or more components of the apparatuses. In some embodiments, a semiconductor processing apparatus includes a wafer handling structure that is configured to support a semiconductor wafer during processing of the semiconductor wafer. The apparatus further includes an ESD prevention layer on the wafer handling structure. The ESD prevention layer includes a first material and a second material, and the second material has an electrical conductivity that is greater than an electrical conductivity of the first material.

Abstract: In some embodiments, an electronic device displays a plurality of content items in a messaging conversation. In some embodiments, the electronic device displays user interfaces associated with one or more content items in a messaging conversation.

Abstract: The embodiment of the present disclosure provides a photovoltaic component control device including at least one bypass module configured to connect in parallel to at least one photovoltaic component; a driving circuit configured to drive the at least one bypass module to operate under control of a controller; a power supply module configured to obtain energy from the at least one photovoltaic component and output the energy to the controller in a case that the at least one photovoltaic component operates normally and the at least one photovoltaic component is bypassed; the controller configured to control an ON state of the at least one bypass module to control whether the at least one photovoltaic component is in a bypass mode. The energy consumption of the control device is greatly reduced, a problem of voltage stress is solved, and the safety performance of the bypass-type control device is improved.

Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

Abstract: The present disclosure relates to IL 12 receptor agonists with improved therapeutic profiles.

Abstract: The present invention provides methods and compositions for treating a lung or heart disease and/or a disease associated with increased expression or activity of integrin ?5?1, comprising administering an integrin ?5?1, inhibitor to a subject. Methods of treating or preventing pulmonary hypertension, pulmonary arterial hypertension (PAH), right ventricle failure, heart failure and fibrosis are also provided herein.

Abstract: Present disclosure provides a transistor structure, including a substrate, a first gate extending along a longitudinal direction over the substrate, the first gate including a gate electrode, a second gate over the substrate and apart from the first gate, a source region of a first conductivity type in the substrate, aligning to an edge in proximity to a side of the first gate, a P-type well surrounding the source region, a drain region of the first conductivity type in the substrate, an N-type well surrounding the drain region, the second gate is entirely within a vertical projection area of the N-type well and a bottom surface of the P-type well and a bottom surface of the N-type well are substantially at a same depth from the first gate.

Abstract: Disclosed are small molecule antagonists of ?4?7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Abstract: An information platform for providing an earthquake early warning of a large area is disclosed. The large area includes a plurality of small districts, different sets of the plurality of small districts form different large districts according to geographical locations so as to make up the large area, and the information platform is both connected with a plurality of on-site earthquake early warning stations and the plurality of small districts through a cloud network. The plurality of on-site earthquake early warning stations are located in the large districts respectively, each of the plurality of on-site earthquake early warning stations is configured to obtain a real-time seismic longitudinal wave measurement data, obtain a real-time seismic transverse wave feature prediction value corresponding to the real-time seismic longitudinal wave measurement data, and transmit the real-time seismic transverse wave feature prediction value.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.